Results 281 to 290 of about 167,999 (361)

The Understudied Landscape of Hidradenitis Suppurativa in Asian Skin of Colour Populations

JEADV Clinical Practice, EarlyView.
Anju George
wiley   +1 more source

Epidemiology and the cost burden of hospitalized pediatric‐onset inflammatory bowel disease in China: A national database study

Pediatric Investigation, EarlyView.
This study provides insights into the clinical characteristics and cost burden of pediatric‐onset inflammatory bowel disease (PIBD) and very early onset IBD (VEO‐IBD) in China. Hospitalizations for PIBD, particularly Crohn's disease, are increasing. Guidelines and health insurance policies can help mitigate the cost burden.
Xiaolu Nie, Jing Li, Hui Xu, Fang Hu, Xiaolin Ye, Mengmeng Yu, Guoshuang Feng, Yueping Zeng, Xin Ni, Jie Wu, Xiaoxia Peng, the Futang Research Center of Pediatric Development (FRCPD)   +11 more
wiley   +1 more source

AGA technical review on perianal Crohn’s disease

, 2003
William J. Sandborn, Victor W. Fazio, Brian G. Feagan, Stephen B. Hanauer   +3 more
openalex   +1 more source

Longstanding Perianal Ulcers

JEADV Clinical Practice, EarlyView.
Narachai Julanon, Thanaphon Anutraungkool, Sirawich Jessadapattarakul, Vincent Piguet   +3 more
wiley   +1 more source

Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta‐Analysis

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
ABSTRACT First‐line therapeutic approaches for Crohn's disease include immunosuppressants, aminosalicylates, and corticosteroids. However, more than one‐third of patients are resistant to these treatments and require second‐line therapies. Our goal was to synthesize the evidence on the efficacy and safety of biologics and small molecules for inducing ...
Daniela Gorski, Raul Edison Luna Lazo, Dalton de Assis de Souza, Helena Hiemisch Lobo Borba, Roberto Pontarolo, Fernanda Stumpf Tonin   +5 more
wiley   +1 more source

An agent transmitting Crohn's disease. [PDF]

Canadian Medical Association journal, 1971
openaire   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

Multiple Ileal and Colonic Stenoses: Is It Always Crohn's Disease? [PDF]

J Crohns Colitis
Bencardino S, Allocca M, Furfaro F, D'Amico F, Parigi TL, Danese S, Zilli A.   +6 more
europepmc   +1 more source

Model‐Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Underexposure to infliximab often leads to loss of response in patients with inflammatory bowel disease (IBD). Model‐informed precision dosing (MIPD) offers a superior approach to maintaining target infliximab concentrations compared to empirical dosage adjustment.
Yoonjin Kim, Seung Hwan Baek, In‐Jin Jang, Jae‐Yong Chung   +3 more
wiley   +1 more source